Generic Medicine Info
Indications and Dosage
Adult: As macrogol 4000 powd: 10-20 g once daily. As macrogol 3350 powd: Initially, 17 g once daily, may be increased to bid depending on the response. Max treatment duration: 1 wk.
Child: As macrogol 4000 powd: ≥8 yr Initially, 10 g every other day, may be increased up to 20 g once daily. Max treatment duration: 3 mth. As macrogol 3350 powd: 4-5 yr Initially, 8.5 g once daily, may be increased up to a max of 17 g once daily according to response. 6-12 yr 17 g once daily. May be increased or decreased according to response. Max: 25.5 g daily. ≥12 yr Same as adult dose. Max treatment duration: 3 mth.
Dissolve powd in 120-240 mL of liq (e.g. water, juice, soda, coffee, tea).
GI disorders (e.g. ileus, intestinal obstruction, ulcerative colitis, toxic megacolon, Crohn’s disease, digestive perforation, painful abdominal syndrome).
Special Precautions
Patient w/ CV disease e.g. CHF, ascitic conditions. Renal impairment. Childn. Pregnancy and lactation.
Adverse Reactions
Significant: Fluid and electrolyte imbalance, hypersensitivity reactions (e.g rash, urticaria, oedema).
GI: Nausea, vomiting, diarrhoea, anal irritation, bloating, abdominal distention, cramps, pain, urgency to defecate, fecal incontinence.
Monitoring Parameters
Assess for symptoms of bowel obstruction prior to treatment.
Symptoms: Diarrhoea, vomiting, abdominal pain, fluid and electrolyte imbalance. Management: Supportive therapy to correct fluid and electrolyte disturbance.
Description: Macrogols or polyethylene glycol (PEG) are long linear polymers w/ osmotic activity. It binds water molecules and retains water in the stool, thus increasing the vol of intestinal fluids causing laxative effect.
Onset: W/in 1 hr.
Absorption: Poorly absorbed from the GI tract.
Excretion: Mainly via faeces (93%); urine (0.2%).
Store between 20-25°C.
MIMS Class
Laxatives, Purgatives
ATC Classification
A06AD15 - macrogol ; Belongs to the class of osmotically acting laxatives.
Anon. Hyperosmotic Laxatives. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 21/07/2017.

Anon. Polyethylene Glycol 3350. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 21/07/2017.

Buckingham R (ed). Macrogols. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 21/07/2017.

Dulcobalance 10 g Powder for Oral Solution in Sachet (Ipsen Ltd). MHRA. Accessed 21/07/17.

Miralax Powder for Solution (Bayer HealthCare LLC.). DailyMed. Source: U.S. National Library of Medicine. Accessed 21/07/2017.

Disclaimer: This information is independently developed by MIMS based on Macrogol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by
  • Blink Intensive Tears
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in